GCP
RVMD icon

GSA Capital Partners’s Revolution Medicines RVMD Stock Holding History

GSA Capital Partners’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,864
Closed -$1.15M – 2119
2026
Q1 		$1.15M Buy
+11,864
New +$1.2M 0.07% 405
2025
Q4 		– Sell
-10,080
Closed -$471K – 2038
2025
Q3 		$471K Buy
10,080
+1,594
+19% +$62.4K 0.04% 884
2025
Q2 		$312K Buy
+8,486
New +$326K 0.02% 1227
2024
Q3 		– Sell
-31,467
Closed -$1.22M – 1959
2024
Q2 		$1.22M Buy
31,467
+23,666
+303% +$885K 0.09% 377
2024
Q1 		$251K Buy
+7,801
New +$231K 0.02% 1302
2023
Q3 		– Sell
-18,762
Closed -$502K – 1847
2023
Q2 		$502K Sell
18,762
-20,595
-52% -$505K 0.05% 731
2023
Q1 		$852K Buy
+39,357
New +$969K 0.08% 402
2022
Q3 		– Sell
-42,184
Closed -$822K – 1818
2022
Q2 		$822K Buy
+42,184
New +$821K 0.12% 215

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

GSA Capital Partners's RVMD Position: Q2 2026 in Review

GSA Capital Partners sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 11,864 shares — an estimated $1.15M sold.

GSA Capital Partners first reported a position in RVMD in Q2 2022 and held it in 8 quarters. The position peaked at $1.22M in Q2 2024. 694 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • GSA Capital Partners reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 11,864 Revolution Medicines shares in Q2 2026, an estimated $1.15M.
  • GSA Capital Partners first reported a position in Revolution Medicines in Q2 2022 and held it in 8 quarters.
  • GSA Capital Partners's Revolution Medicines position peaked at $1.22M in Q2 2024.
  • 694 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.